Falbikitug

法比奇塔单抗

Report date: 2025/02/28 14:32:36

Base Information

Drug NameFalbikitug
Drug Alias NameAZD-0171MSC-1
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanized
Mechanisms of ActionLeukemia inhibitory factor antagonists
TargetsLeukemia inhibitory factor
Therapy Area/IndicationsSolid tumoursCarcinoma, Non-Small-Cell LungOvarian Neoplasms +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCanadaUnited StatesSpain +[4] 
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesAstrazeneca Plc
China Registration ClassN/A

Develop Information

Active CompaniesNorthern Biologics IncAstrazeneca Plc
Inactive CompaniesN/A
Active IndicationsSolid tumours
Inactive IndicationsCarcinoma, Non-Small-Cell LungOvarian NeoplasmsPancreatic Neoplasms

Other Information

ATC CodeN/A
Related LinksN/A